Laurus Labs Limited
General Updates
01 / The disclosure
What the company shared
Laurus Labs Limited has informed the Exchange about Update on Acquisition
A question for your research
Check transaction size, funding, dilution, approvals and completion conditions before assessing the earnings impact.
Numbers found in document text 2 matches
Automatic text matches, not verified financial metrics. A match may come from a table heading or reporting year. Expand it to inspect the surrounding text and original page.
INR 1,078,000,000Page 1
In continuation to our intimation dated April 30, 2026 with regard to further investment in KRKA Pharma Private Limited (“KRKA”), a joint venture company between KRKA d.d., Novo mesto, Slovenia and Laurus Labs Limited (“Company”) and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , we would like to inform you that the Company has invested INR 1,078,000,000/- (Indian Rupees One Billion and Seventy -Eight Million only) and acquired 107,800,000 (One Hundred Seven Million and Eight Hundred Thousand) equity shares of KRKA at face value of INR 10/ - each, aggregating to an amount of IN R 1,078,000,000/- (Indian Rupees One Billion and Seventy-Eight Million only) by way of rights issue.
View source pageINR 10Page 1
In continuation to our intimation dated April 30, 2026 with regard to further investment in KRKA Pharma Private Limited (“KRKA”), a joint venture company between KRKA d.d., Novo mesto, Slovenia and Laurus Labs Limited (“Company”) and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , we would like to inform you that the Company has invested INR 1,078,000,000/- (Indian Rupees One Billion and Seventy -Eight Million only) and acquired 107,800,000 (One Hundred Seven Million and Eight Hundred Thousand) equity shares of KRKA at face value of INR 10/ - each, aggregating to an amount of IN R 1,078,000,000/- (Indian Rupees One Billion and Seventy-Eight Million only) by way of rights issue.
View source pageThe evidence
Read the source excerpts
01In continuation to our intimation dated April 30, 2026 with regard to further investment in KRKA Pharma Private Limited (“KRKA”), a joint venture company between KRKA d.d., Novo mesto, Slovenia and Laurus Labs Limited (“Company”) and in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , we would like to inform you that the Company has invested INR 1,078,000,000/- (Indian Rupees One Billion and Seventy -Eight Million only) and acquired 107,800,000 (One Hundred Seven Million and Eight Hundred Thousand) equity shares of KRKA at face value of INR 10/ - each, aggregating to an amount of IN R 1,078,000,000/- (Indian Rupees One Billion and Seventy-Eight Million only) by way of rights issue.
Page 1
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 106817798
- First collected
- 14 Oct 2026, 20:13 IST
- PDF extraction
- extracted · 1 pages read
- Extraction note
- Source excerpts; financial tables have not been validated.
- Document SHA-256
- d047519f195500c43dd9e6c982f761bc7c83194ed37478eb5eeb15bd5ad7bd2b